Syros Pharmaceuticals Stock News

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -0.79% and 123.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for t

Final results from pivotal study SELECT-MDS-1, using Tamibarotene for the treatment of patients with newly diagnosed high-risk MDS that have RARA gene overexpression, expected Q3 of 2024. The global m

Syros Pharmaceuticals, Inc. (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into furthe

Syros Pharmaceuticals is developing cancer therapies. Its most advanced potential therapy is tamibarotene for MDS.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Karen Hunady - Director-Corporate Communications & Investor Relations Nanc

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 38.36% and 21.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for t

Syros Pharmaceuticals, Inc. (SYRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Syros Pharmaceuticals (SYRS) receives Orphan Drug designation from the FDA for its pipeline candidate AY-5609 being developed for treating metastatic pancreatic cancer. Stock up.

Penny stocks to watch this week. The post Best Penny Stocks To Buy Now That CPI Inflation Data's Out?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Courtney Solberg - Manager of Corporate Communications & Investor Relations N

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conferen

Syros Pharmaceuticals Inc (NASDAQ: SYRS) has agreed to acquire TYME Technologies Inc (NASDAQ: TYME), including its pipeline assets and net cash, after accounting for wind-down and transaction expe

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer,

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Courtney Solberg - Manager, Corporate Communications and IR Nancy Simonian - CE

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 16.67% and 20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc